Precision BioSciences Revenue 2018-2021 | DTIL

Precision BioSciences revenue from 2018 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Precision BioSciences Annual Revenue
(Millions of US $)
2020 $24
2019 $22
2018 $11
2017 $6
Precision BioSciences Quarterly Revenue
(Millions of US $)
2021-06-30 $69
2021-03-31 $16
2020-12-31 $9
2020-09-30 $7
2020-06-30 $1
2020-03-31 $7
2019-12-31 $7
2019-09-30 $5
2019-06-30 $5
2019-03-31 $5
2018-12-31 $5
2018-09-30 $3
2018-06-30 $2
2018-03-31 $2
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.752B $0.024B
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29